Skip to main content
. Author manuscript; available in PMC: 2023 Jan 1.
Published in final edited form as: Thorax. 2021 Jun 10;77(1):22–30. doi: 10.1136/thoraxjnl-2020-216613

Figure 2. Survival analyses in the entire cohort (N=568) during follow-up*.

Figure 2.

*Survival data are censored at 365 days of follow-up. For the hypo-inflammatory versus hyper-inflammatory subphenotype, there was no significant difference in survival beyond 90 days (89% versus 86% of patients surviving beyond 90 days survived through 12-month follow-up, respectively, p=0.70).